IMUGENE LIMITED - News & Media

3.57%

27.0¢

Market Cap $76.45M

Healthcare Biotechnology

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Articles & Videos

Wednesday's HotCopper trends: Imugene cap raise, Lumos distribution deal | July 16

The ASX has headed into a downturn this Wednesday, mostly thanks to U.S. CPI data from June suggesting Trump’s tariffs are finally having an impact on inflation, but that hasn’t stopped several companies flying on the forums.Listen to the HotCopper podcast for in-d...

16 Jul 2025 12:44 (AEST)

Yes, we burn a lot of cash: Imugene issues letter to investors as 1Y returns -72%

As it clocks one year returns down -72%, Imugene Ltd (ASX:IMU) this week issued a letter to shareholders confirming shareholders'...

02 May 2025 13:02 (AEST)

First Aussie doses bring Imugene major step closer to 'quicker, cheaper' non-Hodgkin’s lymphoma care

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic CAR T-cell therapy Azer-cel treatment at the Royal Prince Alfred Hospital in Sydney earlier this week.This dosage marks the start of Imugene’s Phase 1b t...

03 Jan 2025 11:56 (AEDT)

Imugene kicks off Australian trial for blood cancer treatment

Imugene Ltd has opened its first Australian trial for a Phase 1b clinical trial to test CAR T cell therapy azer-cel

08 Nov 2024 13:33 (AEDT)

Imugene's azer-cel trial sees tumours temporarily disappear in 3 of 10 patients

Imugene (ASX:IMU) has announced 3 patients in its latest blood cancer treatment trial using azer-cel have responded well with one showing a complete response for over 100 days. A @complete response’ in this case is a complete disappearance of all tumours. The company is focusing o...

02 Sep 2024 10:14 (AEST)

Imugene doses first cancer patient in Oasis trial

Imugene Limited (ASX: IMU), has dosed the first patient in the phase 1 clinical trial known as OASIS, which is testing its oncolytic virotherapy drug.The clinical trial is targeting adult patients with advanced or metastatic solid tumours. The primary objective of the trial is to evaluate the saf...

24 Jun 2024 09:36 (AEST)

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 27.0¢		Change -0.010(3.57%)		Mkt cap ! $76.45M

Open	High	Low	Value	Volume
28.0¢	28.0¢	26.5¢	$339.1K	1.252M

Buyers (Bids)

No.	Vol.	Price($)
33	595083	26.5¢

Sellers (Offers)

Price($)	Vol.	No.
27.0¢	12605	9

View Market Depth

No.	Vol.	Price($)
33	595083	0.265
32	253529	0.260
15	212876	0.255
29	168136	0.250
9	121914	0.245

Price($)	Vol.	No.
0.270	12573	8
0.275	190734	12
0.280	260538	21
0.285	114871	3
0.290	205200	7

Last trade - 13.17pm 31/07/2025 (20 minute delay)


Last 27.0¢		Change -0.010 ( 1.35 %)
Open	High	Low	Volume
27.0¢	28.0¢	26.5¢	201909
Last updated 13.13pm 31/07/2025 ?

IMU (ASX) Chart

IMUGENE LIMITED - News & Media

Corporate Spotlight
Not Yet Available

Articles & Videos

Wednesday's HotCopper trends: Imugene cap raise, Lumos distribution deal | July 16

Yes, we burn a lot of cash: Imugene issues letter to investors as 1Y returns -72%

First Aussie doses bring Imugene major step closer to 'quicker, cheaper' non-Hodgkin’s lymphoma care

Imugene kicks off Australian trial for blood cancer treatment

Imugene's azer-cel trial sees tumours temporarily disappear in 3 of 10 patients

Imugene doses first cancer patient in Oasis trial

Imugene expands study for bile tract cancer patients

Imugene picks up new virotherapy patent in China

Imugene and NeoImmuneTech team up to improve cancer treatments using T cell therapy

Imugene set to secure European patent for cancer vaccine; announces new phase II CRC cancer trial in 2024

Buyers (Bids)

Sellers (Offers)

Top Stories

IMUGENE LIMITED - News & Media

Corporate SpotlightNot Yet Available

Articles & Videos

Wednesday's HotCopper trends: Imugene cap raise, Lumos distribution deal | July 16

Yes, we burn a lot of cash: Imugene issues letter to investors as 1Y returns -72%

First Aussie doses bring Imugene major step closer to 'quicker, cheaper' non-Hodgkin’s lymphoma care

Imugene kicks off Australian trial for blood cancer treatment

Imugene's azer-cel trial sees tumours temporarily disappear in 3 of 10 patients

Imugene doses first cancer patient in Oasis trial

Imugene expands study for bile tract cancer patients

Imugene picks up new virotherapy patent in China

Imugene and NeoImmuneTech team up to improve cancer treatments using T cell therapy

Imugene set to secure European patent for cancer vaccine; announces new phase II CRC cancer trial in 2024

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available